CTOs on the Move

Dianthus Therapeutics

www.dianthustx.com

 
Dianthus is a biotechnology company dedicated to designing and delivering the next generation of best-in-class monoclonal antibodies with improved selectivity and potency. Led by a multidisciplinary team of seasoned biotech entrepreneurs and scientists, we are pioneering selective antibodies of validated and emerging complement targets to allow people with rare and severe autoimmune diseases live healthier lives to their fullest potential.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.dianthustx.com
  • 203 Crescent Street. Building 4 Suite 205
    Waltham, MA USA 02453
  • Phone: 252.227.7013

Executives

Name Title Contact Details

Similar Companies

Lumos Pharma

Lumos Pharma, based in Austin, Texas, is an early stage biotechnology company created to develop and commercialize a novel treatment for the rare disease Creatine Transporter Deficiency. Lumos Pharma is the exclusive licensee of technology and discoveries made in laboratories at the University of Cincinnati and has partnered with Key Opinion Leaders in the field and the United States National Institutes of Health to ensure success in developing a treatment for Creatine Transporter Deficiency.

Cytokine PharmaSciences

Cytokine PharmaSciences is a King Of Prussia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MB Research Laboratories

MB Research Laboratories is a Spinnerstown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Endobiologics

Endobiologics is a Missoula, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Affigen

Affigen was founded in 2016 by Frameshift, a firm that ideates, translates and launches life sciences companies that have the potential to fundamentally shift the metabolic rate of the industry. In February 2017, Affigen completed its Series A funding, led by Black Beret Life Sciences on behalf of its affiliate BBLS Immunotherapy, LLC. Black Beret Life Sciences is the life sciences investment management arm of the Houston-based Bosarge Family Office. The firm was established in 2014 by Dr. Ed Bosarge to organize and manage investments in potentially game-changing technologies and companies in areas related to regenerative medicine, anti-aging and immunotherapy. Black Beret Life Sciences’ portfolio of managed investments includes companies and research across an array of disease areas, including diabetes, neurodegeneration, osteoarthritis, cancer immunotherapy and various conditions related to aging.